Revenue generating & rising, along with another US$2M expected from NIH.
Two expected CE approvals in Q3:
"Imricor understands that given the advanced stage of the approval processes that Imricor has reached, it would be extremely
unlikely for CE mark approval not to be granted, and Imricor expects that it will receive CE mark approval for the Vision-MR
Ablation Catheter and the Vision-MR Dispersive Electrode in Q3 2019"
Revenue generating & rising, along with another US$2M expected...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.005(0.33%) |
Mkt cap ! $488.6M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.47 | $532.6K | 350.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 340 | $1.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| IMR (ASX) Chart |